The new capital will be used to continue to advance Lycera’s discovery and development efforts and further support the growth of the company.
In conjuction with the funding, Jeffrey Leiden, M.D., Ph.D., managing director at Clarus Venture Partners, joins the company as chairman of the board of directors. In addition, as a result of the company’s progress towards the clinic, Dr. Goldstein joins as the vice president, preclinical development and program management.
Founded in 2006, the company is headquartered in Cambridge, Mass. and has a research center in Ann Arbor, Mich.